| abstract |
Disclosed is 1-(3-tert-butyl-1-p-tolyl-1H-pyrazol-5-yl)-3-(5-fluoro-2-(1-(2-hydroxyethyl)-1H-indazol-5-yloxy)benzyl)urea of formula (I) and compounds of formula (II) and (IV). Also disclosed is the process of making a compound of formula (I), a pharmaceutical composition comprising a compound of formula (I) and the use of a compound of formula (I) or the prodrug 2-(5-(2-((3-(3-tert-butyl-I-p-tolyl-IH-pyrazol-5-yl)ureido )methyl)-4-fluorophenoxy)-1 H-indazol-I-yl)ethyl dihydrogenphosphate in the manufacture of a medicament to treat kinase-mediated conditions particularly inflammatory disease, autoimmune disease, destructive bone disorder, proliferative disorder, infectious disease, viral disease or neurodegenerative disease. |